Medical Establishment BLINDSIDED – Cannabis Compounds Work Where Drugs Failed

Non-intoxicating cannabis compounds CBD and CBG could reverse fatty liver disease affecting one-third of adults worldwide, filling a massive treatment void with plant power.

Story Snapshot

Hebrew University researchers discovered CBD and CBG boost liver energy and cleanup, slashing harmful fats in lab models.
MASLD strikes 33% of adults globally, with no approved drugs—lifestyle fixes often fail long-term.
Team patented CBD-CBG combo, eyeing clinical trials as first potential pharma fix.
CBG excels at cutting body fat and cholesterol; CBD masters blood sugar control.
Novel “backup battery” mechanism in liver uncovered, legitimizing cannabinoids for metabolic woes.

MASLD Crisis: No Drugs for a Global Epidemic

Metabolic dysfunction-associated steatotic liver disease (MASLD) impacts one in three adults worldwide, roughly 2.4 billion people. Obesity, insulin resistance, and high blood pressure drive fat buildup in the liver, the planet’s top chronic liver disorder. Israel sees 60% of adults overweight or obese, with one in five kids affected. No pharmaceutical treatments exist. Diet and exercise help short-term but crumble under real-life pressures, leaving patients vulnerable to progression toward cirrhosis.

Hebrew University Breakthrough: CBD and CBG Mechanisms

Prof. Joseph Tam’s team at Hebrew University of Jerusalem tested non-intoxicating CBD and CBG on MASLD models. Both compounds elevate phosphocreatine, a “backup battery” rarely used in livers, sustaining energy amid high-fat diet stress. They also revive cathepsins in lysosomes, cellular recyclers that dismantle triglycerides and ceramides. Liver cells regain power to process deadly lipids. This dual action marks the first combined test of these cannabinoids for metabolic liver disease.

Publication hit the British Journal of Pharmacology on March 5, 2026. News spread rapidly March 6-10. Tam directs the Multidisciplinary Center for Cannabinoid Research, signaling institutional commitment. Co-researchers Dr. Liad Hinden and PhD student Radka Kočvarová contributed key data. Findings align across peer-reviewed and news sources, with no contradictions.

Differential Powers: CBD vs. CBG Effects

CBD normalizes blood sugar and accelerates glucose clearance, tackling insulin resistance head-on. CBG delivers stronger punches: shrinks body fat mass, heightens insulin sensitivity, drops total cholesterol, and slashes LDL. Both curb harmful liver lipids, but CBG’s broad metabolic wins surprised Tam. These distinctions suggest tailored combos ahead. Common sense favors natural, non-addictive options over synthetic pills, especially absent Big Pharma rivals for MASLD.

Researchers patented the CBD-CBG duo for metabolic disorders, securing their lead. Tam vows clinical trials to deliver the first cannabinoid drug for fatty liver sufferers. Human translation needs validation—lab wins don’t guarantee bedside success. Dosage, safety in people, and timelines stay unclear, demanding caution amid hype.

Stakeholders and Path to Market

Tam holds gatekeeper status via patent and university backing. Pharmaceutical firms eye blockbuster potential in a no-drug market. Patients, burdened by 33% odds, crave options beyond willpower. Regulatory nods could fast-track cannabinoids, proven safe and non-intoxicating. This legitimizes plant medicine, echoing conservative values of self-reliance through nature’s remedies over endless interventions.

Cannabis compounds could reverse disease affecting one-third of adults https://t.co/HGDrGVBVfy #FoxNews

— Rob Klippel (@rjklip) March 10, 2026

Short-term, research sparks cannabinoid programs and patient hope. Long-term, success closes the therapeutic gap, eases healthcare strains, and boosts natural product screening. Russo praises it as elucidating safe benefits. Tam highlights dual remodeling for lipid control. Hebrew University pitches plant-based promise. Facts stack strong, but trials decide reality.